ライフサイエンスコーパス: antimitochondrial antibody

1 er in Dsg3(-/-) KCs nor due to absorption of antimitochondrial antibodies.

2 autoantigen reservoir and the production of antimitochondrial antibodies.

3 hallmark of primary biliary cirrhosis is the antimitochondrial antibody, a highly disease-specific an

4 pathogenic anti-desmoglein (Dsg) 3 +/- 1 and antimitochondrial antibodies (AMA), but it remained unkn

5 titated B-cell levels in all mice as well as antimitochondrial antibodies (AMA), serum and hepatic le

6 ehydrogenase complex (PDC) are the target of antimitochondrial antibodies (AMA).

7 nt with primary biliary cirrhosis (PBC) lack antimitochondrial antibodies (AMA).

8 of anti-BCOADC E2 positive (1/3), and 12% of antimitochondrial antibody (AMA) negative patients with

9 re evaluated for association with PBC and/or antimitochondrial antibody (AMA) positivity with logisti

10 The immunodominant antimitochondrial antibody (AMA) response in primary bil

11 evaluated for association with PBC and with antimitochondrial antibody (AMA) status and prior orthot

12 h PBC with respect to ethnicity, gender, and antimitochondrial antibody (AMA) status; 73 of 535 (13.6

13 f 29 patients who were positive in serum for antimitochondrial antibody (AMA), the disease-specific m

14 ntibodies were detected in 81% (79 of 97) of antimitochondrial antibody (AMA)-positive patients with

15 We hypothesized that antimitochondrial antibodies (AMAs) and development of a

16 n primary biliary cirrhosis (PBC), including antimitochondrial antibodies (AMAs) and extensive portal

17 Antimitochondrial antibodies (AMAs) directed against the

18 the prevalence and unusually high levels of antimitochondrial antibodies (AMAs) in patients with PBC

19 cholestasis, and test positive (>or=90%) for antimitochondrial antibodies (AMAs) in serum.

20 The detection of antimitochondrial antibodies (AMAs) is an important crit

21 Originally, antimitochondrial antibodies (AMAs) were detected by ind

22 aracteristics, and outcomes of patients with antimitochondrial antibodies (AMAs), but no clinical evi

23 biliary cirrhosis (PBC) is characterized by antimitochondrial antibodies (AMAs), directed to the E2

24 is (PBC) characteristically show circulating antimitochondrial antibodies (AMAs), liver-infiltrating

25 eity of patients and the classic hallmark of antimitochondrial antibodies (AMAs).

26 y of liver immunopathology and appearance of antimitochondrial antibodies (AMAs).

27 te dehydrogenase complex E2 subunit (PDC-E2) antimitochondrial antibodies (AMAs).

28 d the prototypic serologic response includes antimitochondrial antibodies (AMAs).

29 genase complex and subsequent development of antimitochondrial antibodies and autoreactive T cells.

30 s (PBC) are characterized by the presence of antimitochondrial antibodies and elevated levels of immu

31 estricted to T cells (dnTGF-betaRII) develop antimitochondrial antibodies and liver inflammation simi

32 ver disease characterized by the presence of antimitochondrial antibodies and the destruction of smal

33 e diagnosis relies on the detection of serum antimitochondrial antibodies directed against a complex

34 The antimitochondrial antibodies from different PV patients

35 Presence of antimitochondrial antibody in serum is almost diagnostic

36 ) is sometimes diagnosed based on a positive antimitochondrial antibody in the appropriate clinical s

37 The downstream signaling of antimitochondrial antibodies involved JNK and late p38 M

38 IL-6(-/-)) and examined for the presence of antimitochondrial antibodies, levels of cytokines, histo

39 ment regimen of 10 consecutive patients with antimitochondrial antibody-positive PBC who had an incom

40 of liver biochemical tests in patients with antimitochondrial antibody-positive PBC who responded in

41 any two of three diagnostic criteria (i.e., antimitochondrial antibody-positive titer >/=1 in 40, ch

42 The immunodominant antimitochondrial antibody response in patients with pri

43 ductopenia associated with the production of antimitochondrial antibodies that react with a protein a

44 The serologic hallmark of PBC is antimitochondrial antibodies that react with the pyruvat

45 made using evidence of cholestasis, positive antimitochondrial antibody titers and liver biopsy findi

46 id not serve as a surrogate antigen allowing antimitochondrial antibodies to enter KCs.

47 Antimitochondrial antibodies were pathogenic because the

48 In addition, antinuclear and antimitochondrial antibodies were present in serum 3 yea